Inclusivity and diversity: Integrating international perspectives on stem cell challenges and potential
By Robin Fears et al.,
Stem Cell Reports
| 07. 29. 2021
Introduction
Scientific advances in regenerative medicine continue to offer great promise in our attempts to tackle intractable diseases, including those presented by aging populations and, potentially, to reduce health care costs. These advances will be applicable worldwide. However, as noted in a recent editorial (Pera, 2020), there is still much to be done to involve hitherto underrepresented groups in their contribution to research and in ensuring that research studies collectively address therapeutic priorities and have the potential to benefit all patients.
In 2020, the InterAcademy Partnership (IAP), the global network of more than 140 academies of science, engineering, and medicine, constituted a working group on regenerative medicine to integrate perspectives from researchers worldwide on the opportunities and challenges in this field with the following objectives:
- To use advances in research and development as rapidly as possible, safely and equitably, to provide new routes to patient benefit worldwide.
- To support medical claims by robust and replicable evidence so that patients and the public are not misled.
This IAP work focused on stem cells for unmet medical needs but it is...
Related Articles
By Rob Stein, NPR | 04.23.2026
The Food and Drug Administration approved the first gene therapy to restore hearing for people who were born deaf.
The decision, while only immediately affecting people born with a very rare form of genetic deafness, is being hailed as...
By Marcelo Jauregui-Volpe, Wired | 04.24.2026
Two companies that launched last year with plans to create gene-edited babies have already shut down, citing money issues and internal conflict.
One of them, Manhattan Genomics of New York, closed abruptly shortly after announcing a team of scientific advisers...
By Alexandre Piquard, Le Monde [cites Katie Hasson] | 04.27.2026
"Si on en prouve la sûreté, nous croyons que l’édition préventive du génome pourrait être l’une des technologies de santé les plus importantes du siècle. » Lucas Harrington explique ainsi le but de son entreprise Preventive : créer des bébés génétiquement modifiés...
By Abby Vesoulis, Mother Jones | 04.18.2026
Two years ago, we devoted an entire issue to the rise of the American oligarchy. Since then, our oligarchic system has become more entrenched and pervasive, revolving around a small crew of tech titans whose quest for wealth and...